Apollo Hospitals Enterprise Ltd

Meeting Details

• Date: August 13, 2026; time not disclosed
• Type: presentation; mode not disclosed
• Event/organiser: Apollo Hospitals Enterprise Limited
• Purpose: discuss unaudited Q1 FY27 results

Participants

• Key company participants: Senior Vice President – Finance; Company Secretary

Availability

• Transcript of the presentation available on the company website

Meeting Details

• Event: Analyst call on financial results for the quarter ended June 30, 2026.
• Type/Mode: Audio recording (virtual analyst call) available online.
• Key participants: Sr. Vice President – Finance and Company Secretary.
• Purpose: Discussion of Q2 2026 results.
• Availability: Recording is available on the company website.

Business overview

• Core business spans Healthcare Services, Diagnostics & AHLL, and Digital Health & Pharmacy Distribution via Apollo HealthCo.
• AHLL's Mother & Child and Fertility units to combine into a major maternity platform.
• Apollo HealthCo is the omni-channel platform integrating digital and offline healthcare services.

Operational highlights

• Commissioned five new hospitals in the last two quarters.
• Total census beds after expansion ~14,100.
• Current beds at Q1FY27: 9,857.
• Expansion plan adds about 1,000 census beds; total project cost ₹11,150 cr, ₹7,500 cr remaining.
• Geographic expansion across Pune, Delhi, Hyderabad, Kolkata, and other Tier-1/Tier-2 cities.
• Of 1,000 beds, 380 operational; 620 to be activated in 12–18 months.

Financial performance

• Consolidated revenue ₹70,435 mn; YoY growth 21%.
• Consolidated EBITDA ₹10,920 mn; margin 15.5%.
• PAT ₹5,805 mn; growth 34%.
• ROCE 28.5% in Q1FY27.
• Hospital segment occupancy 70% established units; average revenue per in-patient ₹186,630.

Capital structure & liquidity

• Cash and equivalents ₹23,560 mn; liquid funds ₹18,555 mn.
• Consolidated net debt ₹7,481 mn.

Strategic priorities & outlook

• Composite scheme approved; demerger of OCP and Apollo 24x7 into NewCo; amalgamation with Keimed.
• Listing expected by Q4 FY27.
• Target run-rate revenue ₹250 bn; EBITDA margin 6.5–7.0%.
• Plan bolt-on acquisitions in Tier-1 cities.

Risks & mitigation

• Execution risk in phased 1,000-bed expansion.
• Integration risk from HealthCo demerger and amalgamation.
• One-time network investment impacting margins.

Governance & leadership

• Shareholder approvals secured for composite scheme; NewCo listing.
• NewCo to be Indian-owned and controlled (IOCC) post approvals.
• Automatic listing of NewCo; AHEL shareholders directly participate.
• Post-merger listing expected by Q4 FY27.

Meeting Details

• Date of investor presentation: August 12, 2026.
• Event type: investor presentation for Q1 FY27 results.
• Organiser: Apollo Hospitals Enterprise Limited.

Participants

• Key company participants: Senior Vice President - Finance and Company Secretary.

Purpose

• Discuss Q1 FY27 results (three months ended June 30, 2026).
• Presentation to investors available on the company website.

Additional Notes

• Presentation enclosed with the filing and uploaded on the company's website.

Financial performance

• Standalone Q1 FY27 revenue from operations Rs 26,561 mn; total income Rs 27,032 mn.
• Standalone EBITDA Rs 6,562 mn; PAT Rs 3,852 mn.
• Standalone Basic EPS Rs 26.79; Diluted Rs 26.78.
• Consolidated Q1 FY27 revenue from operations Rs 70,435 mn; total income Rs 70,923 mn.
• Consolidated PAT attributable to owners Rs 5,807 mn; non-controlling Rs 297 mn; total PAT Rs 6,104 mn.
• Consolidated total comprehensive income Rs 6,143 mn; Basic EPS Rs 40.39; Diluted Rs 40.37.
• Auditors: PwC appointed as statutory auditors for five years from the 46th AGM.
• Deloitte to continue as statutory auditors until the 46th AGM (2027).
• Labour Codes: exceptional item for gratuity and leave liability Rs 192 mn.

Operational highlights & segments

• Beds: 8,352 operating beds; occupancy 70%.
• Healthcare Services revenue Rs 3,567 cr; EBITDA Rs 862 cr; PAT Rs 480 cr.
• AHLL revenue Rs 499 cr; Diagnostics Rs 200 cr; Spectra Rs 80 cr.
• HealthCo revenue Rs 2,977 cr; offline pharmacy Rs 2,629 cr; digital Rs 348 cr; EBITDA Rs 171 cr.
• International patient services revenue growth 26% YoY.
• HealthCo net stores 7,440; 151 net adds in quarter; GMV Rs 535 cr; daily orders ~70,000.
• Consolidated Q1 FY27 revenue grew 21% YoY to Rs 7,043 cr; EBITDA grew 28% to Rs 1,092 cr; PAT Rs 581 cr.
• Apollo 24/7 cost Rs 91 cr in quarter vs Rs 121 cr in Q1 FY26.

Expansion, capex & strategic actions

• 180-bed hospital commissioned at Sarjapur, Bangalore in Q1FY27.
• Gurugram facility on track for commissioning in Q3 FY27.
• Beds expansion plan: total 5,800 beds to be added over five years.
• AHLL to merge with Cloudnine to create maternity/fertility platform.
• AHLL to divest Apollo Specialty Hospitals and Apollo Fertility Centre to Kids Clinic India; EV ~ Rs 15,500 mn; ~9.9% stake.
• Transfer of fast-moving consumer goods business from Apollo Healthco to ACPL on slump sale; subject to approvals.
• Demerger/SCHEME to list resultant company on NSE/BSE; Omni-channel pharmacy & digitalHealth platform involved.

Risks, guidance & outlook

• Labour Codes impact: gratuity and leave liabilities recognized as exceptional items; ongoing monitoring.
• Expansion plan indicates significant capex and capacity growth; execution risk in new markets.
• International patient demand remains a key driver amid regulatory and global travel dynamics.

Meeting Details

• Date and time: 13 August 2026, 3:00 PM IST.
• Type/Mode: group investor conference call; virtual.
• Organizer: Apollo Hospitals Enterprise Ltd (AHEL).
• Participants: Managing Director; Group CFO; President & CEO Hospitals Division.
• Participants (continued): CEO, Apollo HealthCo Ltd.; CEO, AHLL; CFO, Apollo HealthCo Ltd.; CFO, Pharmacy business.
• Purpose: discuss unaudited Q1 FY27 results; results to be announced on Aug 12, 2026.
• Availability: earnings presentation and results will be available on the corporate website.

Meeting Details

• Date and time: Thursday, 13 August 2026 at 3:00 PM IST.
• Type and mode: conference call for analysts/investors (virtual).
• Organizer: Apollo Hospitals Enterprise Limited.
• Purpose: discuss unaudited Q1 FY27 results for quarter ended 30 June 2026.
• Results date: results for quarter ended June 30, 2026 to be announced Aug 12, 2026.
• Key company participants: Managing Director; Group CFO; President & CEO Hospitals Division.
• Additional participants: CFOs of Apollo HealthCo and AHLL; CEO of Apollo HealthCo Ltd.; Pharmacy CFO.
• Results presentation will be available on the corporate website.

Meeting Details

• Board meeting on August 12, 2026; time and venue not disclosed.

Key Agenda Items

• Consider unaudited standalone and consolidated quarterly results for quarter ended 30 June 2026 and related matters.

Other Notes

• Trading window closed from July 1, 2026 to 48 hours after results announcement (by Aug 14, 2026).

Dematerialisation status and listing

• Details of dematerialised securities during the period were furnished to all stock exchanges where listed.
• Security certificates received for dematerialisation were mutilated and cancelled after due verification.
• The depositories' names were substituted as registered owner in the register of members within the prescribed time.
• Securities received for dematerialisation were confirmed (accepted/rejected) to depositories and stock exchanges.

Scheme overview

• Composite arrangement among a listed healthcare company, two transferor entities, and a resultant company.
• Includes separation and independent listing of the resultant healthcare platform.

Purpose

• Intended to unlock value through sharper strategic focus and operational agility.
• Aims to improve capital allocation flexibility and visibility into growth potential.
• Seeks continuity of governance and long-term value creation post-implementation.

Governance and structure

• Resultant company will have a board with six independent directors.
• Promoter and investor board nomination rights are part of the scheme.
• Nomination rights fall away if respective shareholding drops below 10%.
• A lead independent director will be appointed after listing.

Executive appointment

• Proposed executive chairperson appointment is subject to scheme effectiveness and approvals.
• Shareholders will separately approve appointment terms, tenure, and remuneration.

Upside agreement

• Upside arrangement is investor-funded and causes no cash outflow from the company.
• No dilution to the company’s resources or other shareholders is expected.
• Maximum payout is 9% of upside for achieving at least 4x MOIC.

Stakeholder impact

• Employees may be identified as beneficiaries of the upside arrangement.
• Governance framework is designed to preserve stability for shareholders, employees, and other stakeholders.

Status

• Shareholder and creditor meetings have been convened for scheme approval.
• Scheme remains subject to NCLT sanction and subsequent effectiveness.